Literature DB >> 25498866

Development of therapeutics for treatment of Ebola virus infection.

Haoyang Li1, Tianlei Ying1, Fei Yu1, Lu Lu2, Shibo Jiang3.   

Abstract

Ebola virus infection can cause Ebola virus disease (EVD). Patients usually show severe symptoms, and the fatality rate can reach up to 90%. No licensed medicine is available. In this review, development of therapeutics for treatment of Ebola virus infection and EVD will be discussed.
Copyright © 2014 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antibody; Ebola virus; Ebola virus disease; Small-molecule compounds; Therapeutics; Treatment

Mesh：

Substances：

Year:  2014        PMID： 25498866     DOI： 10.1016/j.micinf.2014.11.012

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  16 in total

1.  Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles.

Authors:  Haoyang Li; Fei Yu; Shuai Xia; Yufeng Yu; Qian Wang; Ming Lv; Yan Wang; Shibo Jiang; Lu Lu
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  Artificial infectious disease optimization: A SEIQR epidemic dynamic model-based function optimization algorithm.

Authors:  Guangqiu Huang
Journal:  Swarm Evol Comput       Date:  2015-10-09       Impact factor: 7.177

3.  Cysteine Cathepsin Inhibitors as Anti-Ebola Agents.

Authors:  Wouter A van der Linden; Christopher J Schulze; Andrew S Herbert; Tyler B Krause; Ariel A Wirchnianski; John M Dye; Kartik Chandran; Matthew Bogyo
Journal:  ACS Infect Dis       Date:  2016-01-20       Impact factor: 5.084

4.  Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress.

Authors:  H Marie Loughran; Ziying Han; Jay E Wrobel; Sarah E Decker; Gordon Ruthel; Bruce D Freedman; Ronald N Harty; Allen B Reitz
Journal:  Bioorg Med Chem Lett       Date:  2016-06-23       Impact factor: 2.823

Review 5.  Towards detection and diagnosis of Ebola virus disease at point-of-care.

Authors:  Ajeet Kaushik; Sneham Tiwari; Rahul Dev Jayant; Aileen Marty; Madhavan Nair
Journal:  Biosens Bioelectron       Date:  2015-08-20       Impact factor: 10.618

6.  Integrated sequence and immunology filovirus database at Los Alamos.

Authors:  Karina Yusim; Hyejin Yoon; Brian Foley; Shihai Feng; Jennifer Macke; Mira Dimitrijevic; Werner Abfalterer; James Szinger; Will Fischer; Carla Kuiken; Bette Korber
Journal:  Database (Oxford)       Date:  2016-04-21       Impact factor: 3.451

7.  Contrasting academic and lay press print coverage of the 2013-2016 Ebola Virus Disease outbreak.

Authors:  Mark D Kieh; Elim M Cho; Ian A Myles
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

8.  Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection.

Authors:  Qiang Liu; Changfa Fan; Qianqian Li; Shuya Zhou; Weijin Huang; Lan Wang; Chunyun Sun; Meng Wang; Xi Wu; Jian Ma; Baowen Li; Liangzhi Xie; Youchun Wang
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

9.  Ebola Virus Infection: Overview and Update on Prevention and Treatment.

Authors:  Miguel J Martínez; Abdulbaset M Salim; Juan C Hurtado; Paul E Kilgore
Journal:  Infect Dis Ther       Date:  2015-09-12

10.  SHP-1 suppresses the antiviral innate immune response by targeting TRAF3.

Authors:  Doudou Hao; Yu Wang; Liuyan Li; Gui Qian; Jing Liu; Manman Li; Yihua Zhang; Ruixue Zhou; Dapeng Yan
Journal:  FASEB J       Date:  2020-07-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.